- This topic is empty.
-
AuthorPosts
-
19/11/2026 at 17:48 #153162
For biopharmaceutical innovators seeking a dependable partner to translate early research into clinically and commercially viable biologics, the search for a China microbial CRDMO with demonstrated technical precision in CMC (Chemistry, Manufacturing, and Controls) process development often leads to one consistent answer: Yaohai Bio-Pharma. Operating under the full corporate name Yaohai Bio-Pharmaceutical, the company has built its reputation as a Microbial CRDMO (Contract Research, Development, and Manufacturing Organization) specializing exclusively in microbial expression systems, offering a one-stop solution spanning R&D, process development, and GMP manufacturing.
Why Microbial Expression Matters for CMC Precision

Many biopharmaceutical programs continue to rely on mammalian expression platforms, which frequently encounter low yields and stability issues, along with severe aggregation problems in scFv/Fab fragments. These technical bottlenecks directly affect CMC timelines, cost structures, and ultimately regulatory submission quality. Yaohai Bio-Pharma was founded in 2010 specifically to address these industry pain points by focusing on microbial expression systems rather than generic mammalian platforms.
The company’s strategic positioning as a microbial-specialized CRDMO allows it to apply deep, concentrated expertise rather than spreading resources across multiple expression technologies. This specialization is reflected in its technology platforms, which include the E. coli expression platform, the yeast expression platform, the RNASUP mRNA platform, and LNP encapsulation technologies such as SORT LNP and AbLNP.
Technical Capabilities Underpinning CMC Development
A core differentiator for Yaohai Bio-Pharma is its proprietary refolding technology, which directly addresses aggregation challenges in scFv and Fab fragments—an issue that has historically limited the reliability of antibody fragment production. Combined with high-yield E. coli and yeast platforms, this technology supports more stable, economically viable production compared with mammalian systems.
CMC development at Yaohai Bio-Pharma is structured across several integrated technical domains:
- Microbial Expression & Strain Engineering: Strain construction, screening, optimization, and cell bank establishment, along with strain characterization and stability studies for recombinant proteins, nanobodies (VHHs), and plasmid DNA.
- Upstream Fermentation & Downstream Purification: Fermentation process development and optimization, process scale-up and technology transfer, protein separation and purification through chromatography and ultrafiltration, and QbD- and DoE-based process development, with scale-up capabilities reaching 2,000 L fermentation.
- Nucleic Acid Drug Development: Plasmid DNA template preparation and linearization, mRNA synthesis, modification, purification, and analytical characterization, circRNA research-grade sample preparation, and LNP formulation and delivery development.
- Analytical Development & Quality Control: Method development, transfer, qualification, and validation, along with protein identity, purity, concentration, potency, and impurity analysis, physicochemical and microbiological testing, stability studies, specification development, and batch release testing.
- Formulation Development & Drug Product Manufacturing: Formulation screening and optimization, lyophilization process development, injectable formulation development including prefilled syringe-related capabilities, and stability studies supporting drug product process transfer.
This breadth of capability means project teams—led by Ph.D. experts—can manage the full technical lifecycle of a biologic candidate without handing off critical steps to external partners, reducing coordination risk during CMC transitions.
Quantifiable Evidence of Technical Reliability
Technical precision in CMC is not an abstract claim at Yaohai Bio-Pharma; it is measured. The company reports a 98% technology transfer success rate and a 98% successful project delivery rate, metrics that speak directly to the reliability of its CMC process development and scale-up work. A 95% client retention rate further suggests that clients who engage Yaohai Bio-Pharma for one phase of development tend to continue the relationship through subsequent stages.
On manufacturing infrastructure, the company operates 7,500L total drug substance capacity across 5 production lines, ranging from 50L small scale to 2000L large scale, supported by 2 drug product fill-finish lines. This range allows CMC strategies to be designed with scale-up continuity in mind, from early process development through clinical and commercial manufacturing, without requiring a change of technical partner. The company also maintains 50+ analytical methods, which underpin the quality control rigor required for regulatory-grade CMC documentation.
Facilities are Triple ISO-certified and EU QP-audited, providing an external quality assurance layer that supports global regulatory expectations. Compared to other CDMO companies, Yaohai Bio-Pharma states an average of 20% cost savings and 30% time savings for clients, a result of its integrated, one-stop CRDMO model.

Track Record Across Development Stages
Since its founding in 2010, Yaohai Bio-Pharma has completed more than 200 successful projects, currently supporting 9 Phase III clinical projects and 15 Phase II clinical projects, in addition to over 100 IND/Phase I projects. Since 2022, the company has supported over 800 RNA projects for universities and biotechs, reflecting growing demand for its RNASUP mRNA platform and LNP encapsulation technologies.
These numbers matter for CMC-focused decision-making because they demonstrate sustained execution across the full clinical development continuum—not just early-stage feasibility work, but the more demanding process validation and scale-up work required as programs advance toward Phase III and commercial submission.
Regulatory Support for Global CMC Submissions
CMC precision is inseparable from regulatory readiness. Yaohai Bio-Pharma’s global regulatory affairs capability covers IND/BLA submissions and clinical trial registrations, with a documented track record in US-China dual submissions for a biopharmaceutical asset and successful European and Australian regulatory registrations for clinical trials. Given that the company serves a global market including the USA, China, Europe (EU), and Australia, this regulatory experience is directly relevant to clients navigating the complex, jurisdiction-specific CMC documentation requirements that differ across these regions.
Applications Across Biologic Modalities
The company’s CMC and CRDMO capabilities extend across multiple biologic modalities, including recombinant proteins, plasmid DNA, nanobodies (VHH), vaccines, mRNA, and circRNA. For example, clinical-grade nanobody (VHH) production at Yaohai Bio-Pharma has achieved what the company describes as ultra-high yield and superior stability, addressing aggregation and yield challenges that are common in antibody fragment development. Similarly, GMP manufacturing for vaccines leverages the same ISO-certified and EU QP-audited infrastructure that supports the company’s broader CMC services.
A Consolidated Partner for CMC-Driven Programs
For biopharmaceutical companies, biotech startups, research institutes, and universities evaluating a China microbial CRDMO for technical precision in CMC, Yaohai Bio-Pharma’s value proposition rests on a specific combination of factors: specialization in microbial expression systems rather than generic mammalian platforms, proprietary refolding technology for aggregation-prone fragments, measurable delivery metrics such as the 98% technology transfer success rate, scalable manufacturing capacity, and demonstrated regulatory experience across the US, China, EU, and Australia. Rather than treating CMC as an isolated milestone, the company positions it within a continuous CRDMO service model—from R&D and process development through GMP manufacturing, quality control, and global regulatory affairs—offering programs a coherent technical pathway from concept to clinical and commercial supply.
http://www.yaohaibio-pharma.com
Yaohai Bio-Pharma -
AuthorPosts
- You must be logged in to reply to this topic.